IC
ACRS icon

Ikarian Capital’s Aclaris Therapeutics ACRS Stock Holding History

Ikarian Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,955
Closed -$4.08M – 138
2023
Q3 		$4.08M Sell
5,955
-790,345
-99% -$6.75M 0.49% 54
2023
Q2 		$8.26M Buy
796,300
+64,300
+9% +$582K 1.32% 25
2023
Q1 		$5.92M Buy
+732,000
New +$9.29M 1.34% 24

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ikarian Capital's ACRS Position: Q2 2025 in Review

Ikarian Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 150,900 shares — an estimated $231K sold.

Ikarian Capital first reported a position in ACRS in Q4 2020 and held it in 11 quarters. The position peaked at $4.74M in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Ikarian Capital reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 150,900 Aclaris Therapeutics shares in Q2 2025, an estimated $231K.
  • Ikarian Capital first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 11 quarters.
  • Ikarian Capital's Aclaris Therapeutics position peaked at $4.74M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.